While the company is in discussions to acquire SpringWorks, it did not elaborate on these talks in its earnings call.

DelveInsight’s, “Mesothelioma Pipeline Insight 2025” report provides comprehensive insights about 45+ companies and 50+ ...

AbbVie made a $350 million upfront payment to Gubra for rights to the drug, called GUB014295. Gubra is also eligible to receive another $1.9 billion if certain development and sales milestones are met ...

Elsewhere in the obesity space — Amgen has initiated Phase 3 trials of its obesity drug MariTide, one in overweight and obese ...

On February 10, 2025, the Group confirmed advanced discussions about a potential acquisition of SpringWorks Therapeutics ( SWTX ), Inc., USA. At the time of the preparation of the Consolidated ...

Barclays analyst Peter Lawson says SpringWorks Therapeutics (SWTX) this morning cancelled from the firm’s conference next week, following ...

Ahead of Merck KGaA’s earnings announcement Thursday, investors were mostly looking forward to any comments about its ...

No matter the market environment, you’ll always find entertainment in the biotech space. There will always be biotech stocks ...

Around the world, events are being held to mark Rare Disease Day (28 February 2025), with the aim of bringing attention to ...

Healx has dosed the first patient in a Phase II trial assessing its lead pipeline candidate HLX-1502 in patients with neurofibromatosis type 1 (NF1), while the FDA approved SpringWorks Therapeutics’ ...

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...